Kalytera Provides Data Demonstrating that Prodrug R-107 Provides Sustained Release of Nitric Oxide
June 05, 2020 07:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new in vivo data demonstrating that R-107...
Kalytera Announces Filing of Provisional Patent Protecting Use of R-107 for Treatment of Coronavirus and COVID-19 Associated Pneumonia
June 02, 2020 07:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 02, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that Salzman Group, Inc. has filed a...
Kalytera Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease
May 29, 2020 08:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data demonstrating...
Kalytera Issues CEO Letter to Shareholders
May 25, 2020 07:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, May 25, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today issued the following letter to shareholders from...
Kalytera Announces Binding Agreement to Acquire Salzman Group
May 19, 2020 08:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, May 19, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it has signed a binding Letter of...
Kalytera Announces Updates to Its Annual and Interim Filings
April 28, 2020 16:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") is providing an update on the status of the filing of...
Kalytera and Stero Biotechs Will Not Proceed with Acquisition
April 13, 2020 16:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, April 13, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") has announced that it will not proceed with the...
Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition
March 18, 2020 17:10 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, March 18, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today provided additional details...
Kalytera Announces Extension of Maturity Date of Promissory Note
March 16, 2020 08:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel , March 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that, in...
Kalytera Announces Trading Halt
March 05, 2020 16:58 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO and TEL AVIV, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that the...